
TY  - JOUR
TI  - Abstracts of Papers to be Presented at American Association of Blood Banks. 48 Annual Meeting November 11–15, 1995
JO  - Transfusion
VL  - 35
IS  - S10
SN  - 0041-1132
UR  - https://doi.org/10.1111/j.1537-2995.1995.tb02717.x
DO  - doi:10.1111/j.1537-2995.1995.tb02717.x
SP  - 1s
EP  - 68s
PY  - 1995
ER  - 

TY  - JOUR
TI  - Eighteenth UICC International Cancer Conference June 30–July 5, 2002
JO  - International Journal of Cancer
JA  - Int. J. Cancer
VL  - 100
IS  - S13
SN  - 0020-7136
UR  - https://doi.org/10.1002/ijc.9993
DO  - doi:10.1002/ijc.9993
SP  - 245
EP  - 283
PY  - 2002
ER  - 

TY  - JOUR
TI  - The Centenary (190th) Meeting of the Pathological Society of Great Britain and Ireland, 4 – 7 July 2006
JO  - The Journal of Pathology
JA  - J. Pathol.
VL  - 210
IS  - S1
SN  - 0022-3417
UR  - https://doi.org/10.1002/path.2052
DO  - doi:10.1002/path.2052
SP  - 1A
EP  - 67A
PY  - 2006
ER  - 

TY  - JOUR
TI  - Posters
JO  - Developmental Medicine & Child Neurology
VL  - 43
IS  - s86
SN  - 0012-1622
UR  - https://doi.org/10.1111/j.1469-8749.2001.tb04116.x
DO  - doi:10.1111/j.1469-8749.2001.tb04116.x
SP  - 11
EP  - 39
PY  - 2001
ER  - 

TY  - JOUR
TI  - POSTERS
JO  - Journal of Clinical Periodontology
VL  - 30
IS  - s4
SN  - 0303-6979
UR  - https://doi.org/10.1034/j.1600-051X.30.s4.5.x
DO  - doi:10.1034/j.1600-051X.30.s4.5.x
SP  - 19
EP  - 100
PY  - 2003
ER  - 

TY  - JOUR
TI  - 10th Annual meeting of French Society of Pharmacology, 73rd Annual meeting of Society of Physiology, 27th pharmacovigilance meeting, 54th APNET Seminar and 4th CHU CIC meeting (Corum Montpellier 10-12 April 2006)
JO  - Fundamental & Clinical Pharmacology
VL  - 20
IS  - 2
SN  - 0767-3981
UR  - https://doi.org/10.1111/j.1472-8206.2006.00409.x
DO  - doi:10.1111/j.1472-8206.2006.00409.x
SP  - 145
EP  - 234
PY  - 2006
ER  - 

TY  - JOUR
TI  - Abstracts of the Association of Upper Gastrointestinal Surgeons of Great Britain and Ireland
JO  - BJS (British Journal of Surgery)
JA  - Br J Surg
VL  - 101
IS  - s6
SN  - 0007-1323
UR  - https://doi.org/10.1002/bjs.9694
DO  - doi:10.1002/bjs.9694
SP  - 1
EP  - 54
PY  - 2014
ER  - 

TY  - JOUR
TI  - Wednesday July 5, 2006 17:30–19:00 Hall 1 Schwarz Pharma & Valeant Pharmaceuticals International Satellite Symposium What's around the corner: AEDs in late development
JO  - Epilepsia
VL  - 47
IS  - s3
SN  - 0013-9580
UR  - https://doi.org/10.1111/j.1528-1167.2006.00715_90.x
DO  - doi:10.1111/j.1528-1167.2006.00715_90.x
SP  - 272
EP  - 272
PY  - 2006
AB  - 1 E. Ben-Menachem ( 1 Neurologkliniken, Sahlgrenska Universitetssjukhuset, Goteberg, Sweden ) Lacosamide is in Phase 3 of clinical development for the adjunctive treatment of epilepsy and neuropathic pain. Currently the mode of action (MOA) is under investigation since it has been previously demonstrated that lacosamide does not share a MOA with other currently marketed antiepileptic drugs (AEDs). The drug can be administered orally or intravenously. Results from pharmacokinetic studies suggest that lacosamide has a low potential for drug-drug interactions, and it appears that lacosamide has a minimal risk for affecting the pharmacokinetics of commonly prescribed concomitant AEDs for the treatment of epilepsy. In a double-blind, randomized, placebo-controlled, multicenter trial for the treatment of partial seizures (SP667), lacosamide was administered orally in doses of 200 mg, 400 mg and 600 mg divided in 2 daily doses. In this trial, lacosamide demonstrated a statistically significant reduction in seizure frequency over placebo. Moreover, the 50% responder rate (defined as patients with at least a 50% reduction in seizure frequency) was statistically significant. A further trial (SP616) investigated the safety, tolerability and pharmacokinetics of IV lacosamide as replacement for oral lacosamide in patients with partial-onset seizures. The nature of AEs reported following 60- and 30 minute infusions of lacosamide was consistent with AEs reported following oral administration of lacosamide. Dose-related adverse events include dizziness, nausea, fatigue, ataxia, vision abnormal, diplopia, and nystagmus. The currently available results justify the further development of lacosamide for the treatment of epilepsy.
ER  - 

TY  - JOUR
TI  - The 3rd Congress of Asian Society for Pediatric Research
JO  - Pediatrics International
VL  - 50
IS  - 5
SN  - 1328-8067
UR  - https://doi.org/10.1111/j.1442-200X.2008.02727.x
DO  - doi:10.1111/j.1442-200X.2008.02727.x
SP  - 723
EP  - 792
PY  - 2008
ER  - 

TY  - JOUR
TI  - ASBMR 19th annual meeting
JO  - Journal of Bone and Mineral Research
JA  - J Bone Miner Res
VL  - 12
IS  - S1
SN  - 0884-0431
UR  - https://doi.org/10.1002/jbmr.5650120103
DO  - doi:10.1002/jbmr.5650120103
SP  - S1
EP  - S531
PY  - 1997
ER  - 

TY  - JOUR
AU  - Gonyea, Jay V.
AU  - Watts, Richard
AU  - Applebee, Angela
AU  - Andrews, Trevor
AU  - Hipko, Scott
AU  - Nickerson, Joshua P.
AU  - Thornton, Lindsay
AU  - Filippi, Christopher G.
TI  - In vivo quantitative whole-brain T1 rho MRI of multiple sclerosis
JO  - Journal of Magnetic Resonance Imaging
JA  - J. Magn. Reson. Imaging
VL  - 42
IS  - 6
SN  - 1053-1807
UR  - https://doi.org/10.1002/jmri.24954
DO  - doi:10.1002/jmri.24954
SP  - 1623
EP  - 1630
KW  - T1ρ
KW  - T1 rho
KW  - spin lock
KW  - quantitative MRI
KW  - multiple sclerosis
PY  - 2015
AB  - Background To apply quantitative whole-brain T1-rho (T1?) and T2 imaging to the detection and quantification of brain changes resulting from multiple sclerosis (MS). Methods Twenty-three MS patients with clinically isolated syndrome (10) and relapsing remitting MS (13) phenotypes, compared with 24 age-matched healthy controls were imaged at 3 Tesla. An axial T1?-weighted three-dimensional turbo spin echo sequence with a variable flip angle and fluid suppression was used. Spin-lock times of 0, 20, 40, 60, 80, and 100 ms were used. Corresponding T2 maps were also acquired. Results Whole brain white matter (WM) T1? maps were elevated compared with controls (P = 0.002). WM lesion T1? and T2 values were highly correlated (r = 0.83), but T1? demonstrated 25% better contrast to noise ratio (P < 0.001). WM lesion T1? correlated with disease duration. Gray matter T1? was negatively correlated with the Expanded Disability Status Scale, r = ?0.45, P = 0.03. Normal appearing gray matter and cortical gray matter lesions were negatively correlated on T1?, but not on T2 (rT1? = ?0.63, pT1? = 0.03; rT2 = ?0.17, pT2 = 0.6). Conclusion T1? MRI demonstrates enhanced lesion contrast compared with T2, and in some cases may provide complementary information. T1? may provide a useful measure of demyelinating processes in MS. J. MAGN. RESON. IMAGING 2015;42:1623?1630.
ER  - 

TY  - JOUR
TI  - Podium Presentations
JO  - BJU International
JA  - BJU Int
VL  - 123
IS  - S2
SN  - 1464-4096
UR  - https://doi.org/10.1111/bju.14724
DO  - doi:10.1111/bju.14724
SP  - 29
EP  - 53
PY  - 2019
ER  - 

AU  - Hutmacher, Dietmar W.
AU  - Reichert, Johannes
AU  - Olkowska-Truchanowicz, Joanna
AU  - Leong, David
AU  - Lim, Thiam Chye
C7  - pp. 439-462
TI  - Characterization and Culturing of Adipose-Derived Precursor Cells
SN  - 9780470146934
UR  - https://doi.org/10.1002/9780470454923.ch24
DO  - doi:10.1002/9780470454923.ch24
SP  - 439-462
KW  - bone marrow mesenchymal stem cells (BM-MSCs) – promising candidate stem cells in regenerative medicine
KW  - specific proliferation and differentiation capacity of adipose-derived cells (ADSCs)
KW  - ADSCs and increasing angiogenesis to ischemic tissue - applications in regenerative medicine
PY  - 2019
AB  - Summary This chapter contains sections titled: Introduction Description of the Adipose Tissue Pump Versus Syringe Procedure Adipose-Derived Stem Cells (ADSCs) Properties and Characterization Cell Surface Characterization Differentiation Potential of Adipose Stem Cells Specific Proliferation and Differentiation Capacity of ADSCs Adipogenic Lineage Osteogenesis Potential Applications in Regenerative Medicine Conclusion References
ER  - 

AU  - Leary, Siobhan
AU  - Giovannoni, Gavin
AU  - Howard, Robin
AU  - Miller, David
AU  - Thompson, Alan
C7  - pp. 411-447
TI  - Multiple Sclerosis and Demyelinating Diseases
SN  - 9781405134439
UR  - https://doi.org/10.1002/9781444311709.ch10
DO  - doi:10.1002/9781444311709.ch10
SP  - 411-447
KW  - multiple sclerosis and demyelinating diseases
KW  - autoimmune pathogenesis
KW  - secondary progressive multiple sclerosis
KW  - primary progressive multiple sclerosis
KW  - progressive relapsing multiple sclerosis
KW  - benign multiple sclerosis
KW  - aggressive multiple sclerosis
KW  - factors affecting relapse activity
KW  - Alexander's disease - rare form of leucodystrophy
KW  - Hematopoietic stem cell transplantation
PY  - 2019
AB  - Summary This chapter contains sections titled: Introduction Epidemiology Aetiology Pathophysiology Clinical course Clinical features Diagnosis Management Neuromyelitis optica Acute para-infectious inflammatory encephalopathies Leucodystrophies References
ER  - 

TY  - JOUR
TI  - XXIIIrd Congress of the ISBT Abstracts
JO  - Vox Sanguinis
VL  - 67
IS  - s2
SN  - 9781405134439
UR  - https://doi.org/10.1111/j.1423-0410.1994.tb03669.x
DO  - doi:10.1111/j.1423-0410.1994.tb03669.x
SP  - 1
EP  - 174
PY  - 1994
ER  - 

AU  - Flowers, Mary E. D.
AU  - Deeg, H. Joachim
C7  - pp. 944-961
TI  - Delayed Complications After Hematopoietic Cell Transplantation
SN  - 9781405112567
UR  - https://doi.org/10.1002/9780470987070.ch69
DO  - doi:10.1002/9780470987070.ch69
SP  - 944-961
KW  - hematopoietic cell transplantation [HCT]
KW  - anemia
KW  - etiology
KW  - cardiac disease
KW  - hepatic complications
PY  - 1994
AB  - Summary This chapter contains sections titled: Introduction Etiology and spectrum of delayed complications Chronic GVHD Infections Airway and pulmonary disease Dysregulation of immunity Hematologic problems Neuroendocrine dysfunction Cardiovascular disease Ocular problems Musculofascial problems Skeletal complications Dental problems Genitourinary dysfunction Gastrointestinal and hepatic complications Posttransplant malignancies Nervous system Psychosocial effects and rehabilitation Recent developments Summary
ER  - 

TY  - JOUR
TI  - FREE COMMUNICATIONS
JO  - Journal of the European Academy of Dermatology and Venereology
VL  - 19
IS  - s2
SN  - 9781405112567
UR  - https://doi.org/10.1111/j.1468-3083.2005.01310.x
DO  - doi:10.1111/j.1468-3083.2005.01310.x
SP  - 1
EP  - 58
PY  - 2005
ER  - 

TY  - JOUR
TI  - TSANZ Poster Abstracts
JO  - Respirology
JA  - Respirology
VL  - 18
IS  - S2
SN  - 9781405112567
UR  - https://doi.org/10.1111/resp.12046
DO  - doi:10.1111/resp.12046
SP  - 38
EP  - 85
PY  - 2013
ER  - 

TY  - JOUR
TI  - Poster Sessions
JO  - Tropical Medicine & International Health
JA  - Trop Med Int Health
VL  - 20
IS  - S1
SN  - 9781405112567
UR  - https://doi.org/10.1111/tmi.12574
DO  - doi:10.1111/tmi.12574
SP  - 171
EP  - 441
PY  - 2015
ER  - 

TY  - JOUR
TI  - Poster Tours
JO  - Pediatric Diabetes
JA  - Pediatr Diabetes
VL  - 14
IS  - s18
SN  - 9781405112567
UR  - https://doi.org/10.1111/pedi.12075
DO  - doi:10.1111/pedi.12075
SP  - 50
EP  - 154
PY  - 2013
ER  - 
